Patents by Inventor Siegfried Schneider

Siegfried Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160199383
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: March 18, 2016
    Publication date: July 14, 2016
    Inventors: Siegfried SCHNEIDER, Dirk KESSLER, Lars van der VEEN, Tobias WUNBERG
  • Patent number: 9321771
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: April 26, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Siegfried Schneider, Dirk Kessler, Lars van der Veen, Tobias Wunberg
  • Patent number: 9243000
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: January 26, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lars Van Der Veen, Darryl McConnell, Siegfried Schneider, Matthias Grauert, Andreas Schoop, Tobias Wunberg
  • Patent number: 9218584
    Abstract: A method is proposed for determining clinical study compliance. The method includes obtaining criteria for the clinical study and accessing stored clinical data relating to the clinical study. Thereafter, the criteria and clinical data are correlated to determine a measure of compliance with the criteria of the clinical study.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: December 22, 2015
    Assignee: Siemens Aktiengesellschaft
    Inventors: Klaus Abraham-Fuchs, Gudrun Zahlmann, Rainer Kuth, Eva Rumpel, Siegfried Schneider, Markus Schmidt, Horst Schreiner
  • Patent number: 9152939
    Abstract: A method is proposed for determining clinical study compliance. The method includes obtaining criteria for the clinical study and accessing stored clinical data relating to the clinical study. Thereafter, the criteria and clinical data are correlated to determine a measure of compliance with the criteria of the clinical study.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: October 6, 2015
    Assignee: Siemens Aktiengesellschaft
    Inventors: Klaus Abraham-Fuchs, Gudrun Zahlmann, Rainer Kuth, Eva Rumpel, Siegfried Schneider, Markus Schmidt, Horst Schreiner
  • Patent number: 9090564
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, m and n are defined as in the specification, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Siegfried Schneider, Lars Van Der Veen
  • Patent number: 8916548
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: December 23, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tobias Wunberg, Ralph Brueckner, Dirk Kessler, Oliver Kraemer, Darryl McConnell, Siegfried Schneider, Lars van der Veen
  • Patent number: 8815855
    Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: August 26, 2014
    Assignee: 4SC AG
    Inventors: Thomas Maier, Thomas Bär, Thomas Beckers, Astrid Zimmermann, Siegfried Schneider, Volker Gekeler
  • Publication number: 20140073621
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Siegfried SCHNEIDER, Dirk KESSLER, Lars van der VEEN, Tobias WUNBERG
  • Patent number: 8633183
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: January 21, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Siegfried Schneider, Dirk Kessler, Lars van der Veen, Tobias Wunberg
  • Patent number: 8618111
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: December 31, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Siegfried Schneider, Dirk Kessler, Lars van der Veen, Tobias Wunberg
  • Publication number: 20130253945
    Abstract: A method is proposed for determining clinical study compliance. The method includes obtaining criteria for the clinical study and accessing stored clinical data relating to the clinical study. Thereafter, the criteria and clinical data are correlated to determine a measure of compliance with the criteria of the clinical study.
    Type: Application
    Filed: May 16, 2013
    Publication date: September 26, 2013
    Inventors: Klaus ABRAHAM-FUCHS, Gudrun ZAHLMANN, Rainer KUTH, Eva RUMPEL, Siegfried SCHNEIDER, Markus SCHMIDT, Horst SCHREINER
  • Publication number: 20130253944
    Abstract: A method is proposed for determining clinical study compliance. The method includes obtaining criteria for the clinical study and accessing stored clinical data relating to the clinical study. Thereafter, the criteria and clinical data are correlated to determine a measure of compliance with the criteria of the clinical study.
    Type: Application
    Filed: May 16, 2013
    Publication date: September 26, 2013
    Inventors: Klaus ABRAHAM-FUCHS, Gudrun ZAHLMANN, Rainer KUTH, Eva RUMPEL, Siegfried SCHNEIDER, Markus SCHMIDT, Horst SCHREINER
  • Patent number: 8529446
    Abstract: In a method for determining a parameter in an automatic study and data management system, data is gathered in a knowledge database, and a parameter is determined based the data gathered in the knowledge database. The data is correlated to at least one of a configuration and implementation of a previous clinical study. The parameter is usable for configuring a future clinical study.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: September 10, 2013
    Assignee: Siemens Aktiengesellschaft
    Inventors: Markus Schmidt, Siegfried Schneider, Gudrun Zahlmann
  • Patent number: 8515774
    Abstract: A method is proposed for determining clinical study compliance. The method includes obtaining criteria for the clinical study and accessing stored clinical data relating to the clinical study. Thereafter, the criteria and clinical data are correlated to determine a measure of compliance with the criteria of the clinical study.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: August 20, 2013
    Assignee: Siemens Aktiengesellschaft
    Inventors: Klaus Abraham-Fuchs, Gudrun Zahlmann, Rainer Kuth, Eva Rumpel, Siegfried Schneider, Markus Schmidt, Horst Schreiner
  • Publication number: 20130196975
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, m and n are defined as in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: March 12, 2013
    Publication date: August 1, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Tobias WUNBERG, Siegfried SCHNEIDER, Lars VAN DER VEEN
  • Patent number: 8304556
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: November 6, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Maria Impagnatiello, Dirk Kessler, Oliver Kraemer, Siegfried Schneider, Lars Van Der Veen, Ulrike Weyer-Czernilofsky, Tobias Wunberg
  • Patent number: 8288379
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: October 16, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lars Van Der Veen, Maria Impagnatiello, Darryl McConnell, Siegfried Schneider, Tobias Wunberg
  • Publication number: 20120108618
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 3, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lars Van Der Veen, Darryl Mcconnell, Siegfried Schneider, Matthias Grauert, Andreas Schoop, Tobias Wunberg
  • Publication number: 20120108567
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 3, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Darryl McCONNELL, Maria IMPAGNATIELLO, Dirk KESSLER, Oliver KRAEMER, Siegfried SCHNEIDER, Lars VAN DER VEEN, Ulrike WEYER-CZERNILOFSKY, Tobias WUNBERG